.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
UBS
Healthtrust
McKesson
US Department of Justice
Covington
Dow
Baxter
Fuji
Merck

Generated: June 27, 2017

DrugPatentWatch Database Preview

Nevirapine - Generic Drug Details

« Back to Dashboard

What are the generic sources for nevirapine and what is the scope of nevirapine patent protection?

Nevirapine
is the generic ingredient in three branded drugs marketed by Aurobindo, Sandoz Inc, Aurobindo Pharma Ltd, Alvogen Malta, Apotex Inc, Mylan Pharms Inc, Boehringer Ingelheim, Prinston Inc, Cipla Ltd, Cipla, Mylan Labs, Sciegen Pharms Inc, Micro Labs Ltd, Hetero Labs Ltd Iii, and Strides Pharma, and is included in twenty-two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Nevirapine has thirty patent family members in twenty-seven countries.

There are twenty drug master file entries for nevirapine. Nineteen suppliers are listed for this compound. There are seven tentative approvals for this compound.

Summary for Generic Name: nevirapine

Tradenames:3
Patents:2
Applicants:15
NDAs:22
Drug Master File Entries: see list20
Suppliers / Packagers: see list19
Bulk Api Vendors: see list77
Clinical Trials: see list199
Patent Applications: see list5,599
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:nevirapine at DailyMed

Tentative approvals for NEVIRAPINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe50MGTABLET; ORAL
► Subscribe► Subscribe200MGTABLET; ORAL
► Subscribe► Subscribe200MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL203411-001Apr 3, 2014ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL207698-001Feb 28, 2017ABRXNoNo► Subscribe► Subscribe
Cipla Ltd
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL206448-001Oct 15, 2015ABRXNoNo► Subscribe► Subscribe
Alvogen Malta
NEVIRAPINE
nevirapine
TABLET, EXTENDED RELEASE;ORAL204621-001Jul 10, 2015ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
NEVIRAPINE
nevirapine
TABLET;ORAL202523-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: nevirapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
VIRAMUNE
nevirapine
SUSPENSION;ORAL020933-001Sep 11, 19985,366,972*PED► Subscribe
Boehringer Ingelheim
VIRAMUNE XR
nevirapine
TABLET, EXTENDED RELEASE;ORAL201152-001Mar 25, 20115,366,972*PED► Subscribe
Boehringer Ingelheim
VIRAMUNE
nevirapine
TABLET;ORAL020636-001Jun 21, 19965,366,972*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: nevirapine

Country Document Number Estimated Expiration
Uruguay31128► Subscribe
Peru10352013► Subscribe
Spain2574836► Subscribe
Colombia6150128► Subscribe
South Africa200904939► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEVIRAPINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90022Netherlands► SubscribePRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
/1999Austria► SubscribePRODUCT NAME: NEVIRAPINE; REGISTRATION NO/DATE: EU/1/97/055/001 19980205
C/GB99/020United Kingdom► SubscribePRODUCT NAME: NEVIRAPINE = 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: CH 54393 19971223; UK EU/1/97/055/001 19980205
C0021Belgium► SubscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223
C0019France► SubscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
Medtronic
McKesson
Fuji
Cerilliant
Fish and Richardson
Johnson and Johnson
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot